Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tranexamic Acid for Recovery After Modified Radical Mastoidectomy in Patients With Chronic Suppurative Otitis Media

18. november 2026 oppdatert av: Haiyan An, MD, Peking University People's Hospital

Clinical Study on the Application of Tranexamic Acid to Improve the Prognosis of Surgical Treatment for Chronic Suppurative Otitis Media

The main objective of this project is to conduct a multicentre, prospective, randomised, controlled clinical trial to evaluate the clinical value of tranexamic acid in patients undergoing mastoidectomy. The study population consists of patients with chronic suppurative otitis media scheduled to undergo mastoidectomy. They will be randomised in a 1:1 ratio to either the pre-operative intravenous tranexamic acid group or the saline control group; both groups will undergo treatment in accordance with standardised anaesthesia and surgical protocols. The main research components include:

  1. Evaluation of the dry ear rate: The primary outcome measure was to compare the difference in dry ear rates between the two groups one month post-operatively, in order to verify the effect of tranexamic acid on improving the dry ear rate following mastoidectomy. The assessment of the dry ear rate was carried out by an ENT specialist unaware of the study group allocation via clinical otoscopic examination; a dry ear was defined as the absence of discharge in the ear canal and complete epithelialisation of the mastoid surgical site. The assessment time point for the primary outcome measure was one month post-operatively.
  2. Postoperative hearing assessment: This will be assessed based on the improvement in hearing at 3 months postoperatively compared with preoperative levels.
  3. Safety assessment: The safety assessment will primarily include common adverse reactions associated with the use of tranexamic acid (e.g. nausea, vomiting, dizziness) and serious adverse events (e.g. venous thromboembolism, myocardial infarction, epileptic seizures). These will be comprehensively evaluated in conjunction with clinical signs and laboratory tests to ensure the safety and feasibility of the intervention.

Through this study, the project aims to determine whether tranexamic acid can effectively reduce the incidence of dry ear in the early postoperative period following mastoidectomy, and to provide evidence-based support for its clinical implementation.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

202

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100034
        • Peking University First Hospital
        • Ta kontakt med:
      • Beijing, Beijing Municipality, Kina, 100044
        • Peking University People's Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18-65 years, regardless of sex
  • American Society of Anesthesiologists (ASA) physical status I-II
  • Patients diagnosed with chronic suppurative otitis media (CSOM) who have had an inadequate response to conservative medical treatment
  • Patients scheduled to undergo microscopic open (canal wall-down) radical mastoidectomy
  • Patients who provide written informed consent

Exclusion Criteria:

  • Known allergy or hypersensitivity to tranexamic acid (TXA)
  • Severe hepatic or renal disease (hepatic or renal decompensation); thromboembolic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction; a history of epilepsy, including seizures induced by any cause; or coagulation disorders (any of the following coagulation parameters-activated partial thromboplastin time [APTT], prothrombin time [PT], fibrinogen [FIB], or D-dimer [D-D]-exceeding 1.5 times the upper limit of the normal range)
  • Use of anticoagulant or antiplatelet medications within 2 weeks before surgery, including aspirin, clopidogrel, warfarin, or other such medications
  • Color blindness, pregnancy, or breastfeeding

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Normal Saline (NS) Group

An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision.

An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision.

Eksperimentell: Tranexamic Acid (TXA) Group

Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision.

Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Dry ear rate
Tidsramme: 1 month (±1 week) after surgery

A dry ear is defined as no exudate in the external auditory canal or mastoid cavity and complete epithelialization of the surgical cavity. Dry ear status will be assessed by an otolaryngologist using otoendoscopy.

1 month (±1 week) after surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hearing improvement
Tidsramme: 3 months after surgery (±2 weeks)

Pure-tone audiometry will be used to assess hearing thresholds at 0.5, 1, 2, and 4 kHz. Air-conduction (AC), bone-conduction (BC), and air-bone gap (ABG) thresholds will be recorded at each frequency.

3 months after surgery (±2 weeks)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and tolerability
Tidsramme: At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)

Adverse events will be assessed at postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks), including common adverse events such as nausea, vomiting, and dizziness, as well as serious adverse events such as arterial or venous thromboembolism, myocardial infarction, and seizures. These assessments will be used to evaluate the safety of preoperative intravenous administration of tranexamic acid in patients undergoing modified radical mastoidectomy.

At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

25. november 2026

Primær fullføring (Antatt)

30. september 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

15. november 2026

Først innsendt som oppfylte QC-kriteriene

18. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026PHB663-001
  • 首发2026-2-4085 (Annet stipend/finansieringsnummer: Beijing Municipal Health Commission)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared with other researchers due to patient privacy and confidentiality considerations, as well as institutional data protection requirements. Only aggregated study results may be made publicly available through scientific publications.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere